D-0869-2023 Class II Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0869-2023 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on May 3, 2023 and is designated Class II. Reason for recall: CGMP Deviations The recall status is terminated (terminated Jan 9, 2024). Affected quantity: 12,336 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 14, 2023
Initiation Date
May 3, 2023
Termination Date
Jan 9, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,336 bottles

Product description

Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83.

Reason for recall

CGMP Deviations

Distribution pattern

Product was distributed to 19 distributors nationwide.

Code information

Lot #: DND1515A, Exp 08/24

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0869-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0869-2023. Report a data issue: hello@regdatalab.com.